{"title":"Atherosclerosis as a Neuroimmune and Neurovascular Disorder: Pharmacological Opportunities Beyond Lipid Lowering.","authors":"Francisco Epelde","doi":"10.2174/011570159X518272260820062846","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction/objective: </strong>Atherosclerosis is traditionally defined as a lipid-driven inflammatory disease of medium and large arteries, but vascular inflammation also interacts with immune, autonomic, metabolic, and brain vascular pathways. This narrative review synthesizes evidence supporting an artery-immune-brain framework and identifies pharmacological opportunities beyond lipid-lowering and antithrombotic therapy.</p><p><strong>Methods: </strong>A targeted narrative review was performed using PubMed/MEDLINE, Google Scholar, and publisher databases, with priority given to randomized trials, guidelines, meta-analyses, and high-quality translational studies. Evidence was interpreted in accordance with translational maturity, distinguishing established clinical evidence from mechanisms that remain preclinical, indirect, or hypothesis-generating.</p><p><strong>Results: </strong>Established evidence supports intensive lipid lowering, residual inflammatory-risk assessment, and selected anti-inflammatory and cardiometabolic strategies in atherosclerotic disease. Translational evidence further suggests that adventitial immune-neural niches, autonomic imbalance, trained immunity, gut-derived metabolites, vascular senescence, blood-brain barrier dysfunction, and neurovascular-unit injury may amplify vascular and cognitive risk. These mechanisms differ substantially in clinical readiness.</p><p><strong>Discussion: </strong>The artery-immune-brain model helps explain residual vascular risk that is not fully captured by LDL-C, luminal stenosis, or recurrent ischemic events alone. It also supports trial designs that combine vascular, inflammatory, neuroimaging, cognitive, safety, and health-economic endpoints.</p><p><strong>Conclusion: </strong>Atherosclerosis should be viewed as a lipid-inflammatory disease with clinically established vascular consequences, and additional neuroimmune and neurovascular mechanisms that are promising but require phenotype-specific validation before therapeutic translation.</p>","PeriodicalId":10905,"journal":{"name":"Current Neuropharmacology","volume":" ","pages":""},"PeriodicalIF":6.1000,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Neuropharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/011570159X518272260820062846","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction/objective: Atherosclerosis is traditionally defined as a lipid-driven inflammatory disease of medium and large arteries, but vascular inflammation also interacts with immune, autonomic, metabolic, and brain vascular pathways. This narrative review synthesizes evidence supporting an artery-immune-brain framework and identifies pharmacological opportunities beyond lipid-lowering and antithrombotic therapy.
Methods: A targeted narrative review was performed using PubMed/MEDLINE, Google Scholar, and publisher databases, with priority given to randomized trials, guidelines, meta-analyses, and high-quality translational studies. Evidence was interpreted in accordance with translational maturity, distinguishing established clinical evidence from mechanisms that remain preclinical, indirect, or hypothesis-generating.
Results: Established evidence supports intensive lipid lowering, residual inflammatory-risk assessment, and selected anti-inflammatory and cardiometabolic strategies in atherosclerotic disease. Translational evidence further suggests that adventitial immune-neural niches, autonomic imbalance, trained immunity, gut-derived metabolites, vascular senescence, blood-brain barrier dysfunction, and neurovascular-unit injury may amplify vascular and cognitive risk. These mechanisms differ substantially in clinical readiness.
Discussion: The artery-immune-brain model helps explain residual vascular risk that is not fully captured by LDL-C, luminal stenosis, or recurrent ischemic events alone. It also supports trial designs that combine vascular, inflammatory, neuroimaging, cognitive, safety, and health-economic endpoints.
Conclusion: Atherosclerosis should be viewed as a lipid-inflammatory disease with clinically established vascular consequences, and additional neuroimmune and neurovascular mechanisms that are promising but require phenotype-specific validation before therapeutic translation.
期刊介绍:
Current Neuropharmacology aims to provide current, comprehensive/mini reviews and guest edited issues of all areas of neuropharmacology and related matters of neuroscience. The reviews cover the fields of molecular, cellular, and systems/behavioural aspects of neuropharmacology and neuroscience.
The journal serves as a comprehensive, multidisciplinary expert forum for neuropharmacologists and neuroscientists.